CALYPTE DISCUSSIONS WITH FDA ABOUT CONFIRMATORY HIV URINE TEST CONTINUE; AGENCY APPROVES FIRM'S URINE SAMPLE HIV-1 TEST AS PRELIMINARY SCREEN
This article was originally published in The Gray Sheet
Calypte Biomedical is continuing talks with FDA concerning the data requirements for approval of a urine-based HIV-1 confirmatory test to complement the company's Calypte HIV-1 Urine EIA screening test. The screening test was approved by the agency on Aug. 6.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.